PURE Bioscience Balance Sheet

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Cash & Equivalents	0.98	0.33	0.35	1.1	3.39	2.39
Cash & Short-Term Investments	0.98	0.33	0.35	1.1	3.39	2.39
Cash Growth	82.04%	-4.30%	-68.13%	-67.71%	41.88%	-37.74%
Receivables	0.24	0.47	0.3	0.29	0.2	0.37
Inventory	0.23	0.14	0.06	0.09	0.18	0.33
Prepaid Expenses	0.02	0.02	0.03	0.06	0.02	0.03
Restricted Cash	0.08	0.08	0.08	0.08	0.08	0.08
Total Current Assets	1.55	1.05	0.81	1.6	3.86	3.2
Property, Plant & Equipment	0.01	0.01	0.01	0.22	0.62	0.74
Other Intangible Assets	-	-	-	-	-	0.37
Total Assets	1.56	1.06	0.82	1.83	4.48	4.3
Accounts Payable	0.72	0.78	0.6	0.42	0.49	0.59
Accrued Expenses	0.18	0.15	0.13	0.11	0.09	0.14
Short-Term Debt	-	-	-	-	-	0.24
Total Current Liabilities	3.65	0.94	0.73	0.53	0.58	0.97
Long-Term Debt	3.74	5.24	2.95	1.02	-	-
Total Liabilities	7.4	6.17	3.68	1.55	0.58	0.97
Common Stock	1.3	1.12	1.12	1.12	1.11	0.87
Additional Paid-In Capital	133.73	132.76	132.61	132.4	132.08	128.25
Retained Earnings	-140.87	-138.99	-136.6	-133.25	-129.28	-125.79
Shareholders' Equity	-5.84	-5.12	-2.86	0.27	3.91	3.33
Total Liabilities & Equity	1.56	1.06	0.82	1.83	4.48	4.3
Total Debt	6.5	5.24	2.95	1.02	-	0.24
Net Cash (Debt)	-5.51	-4.9	-2.6	0.07	3.39	2.15
Net Cash Growth	-	-	-	-97.82%	57.65%	-43.97%
Net Cash Per Share	-0.05	-0.04	-0.02	0.00	0.04	0.02
Filing Date Shares Outstanding	130.02	111.89	111.86	111.86	111.36	87.22
Total Common Shares Outstanding	130.02	111.89	111.86	111.86	111.36	87.22
Working Capital	-2.11	0.11	0.07	1.07	3.29	2.23
Book Value Per Share	-0.04	-0.05	-0.03	0.00	0.04	0.04
Tangible Book Value	-5.84	-5.12	-2.86	0.27	3.91	2.97
Tangible Book Value Per Share	-0.04	-0.05	-0.03	0.00	0.04	0.03
Machinery	-	1.62	1.62	1.62	1.58	1.52
Construction In Progress	-	-	-	-	0.08	0.06